中國聖牧(01432.HK)完成收購12家牧場公司少數權益
格隆匯6月1日丨中國聖牧(01432.HK)發佈公告,有關公司、12名自然人股東與聖牧高科就收購12家牧場公司少數權益及根據特別授權發行代價股份訂立的股權轉讓框架協議。相關所載收購事項涉及所有先決條件均已達成及收購事項已於2020年5月29日完成。緊隨交易完成前,公司已發行股份為63.544億股。
交易完成後,根據股東於股東特別大會上授予的特別授權,公司按每股代價股份0.33港元發行價已向BVI1妥當配發及發行約6.887億股新股份,相當於該公告日期公司經發行代價股份擴大後已發行股本約9.78%。因此,緊隨交易完成後,已發行股份約為70.431億股。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.